Crinetics CEO sells shares for tax withholding

Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported tax-related share sales.

Rhea-AI Filing Summary

Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported tax-related share sales. On March 16, 2026, he sold a total of 21,981 shares of common stock in open-market transactions, including 13,196 shares at a volume-weighted average price of $37.11 and 8,785 shares at $37.77.

According to the disclosure, these shares were sold by a broker to cover the CEO's tax withholding obligations upon the vesting of restricted stock units granted on February 28, 2022, March 1, 2023, and March 4, 2024, under a Rule 10b5-1 trading plan. After the sales, he directly holds 404,778 shares of common stock and has additional indirect holdings through several family trusts and his spouse.

Insider Trade Summary 10b5-1

Net Seller: 21,981 shares

Net Sell 7 txns

Insider Struthers Richard Scott

Role President & CEO

Sold 21,981 shs ($822K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,196	$37.11	$490K
Sale	Common Stock	8,785	$37.77	$332K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 404,778 shares (Direct); Common Stock — 661,205 shares (Indirect, By Family Trust 1); Common Stock — 106,000 shares (Indirect, By Family Trust 2); Common Stock — 110,000 shares (Indirect, By Family Trust 3); Common Stock — 100,000 shares (Indirect, By Family Trust 4); Common Stock — 1,000 shares (Indirect, By Spouse)

Footnotes (3)

1. F1. Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. F2. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
3. F3. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

FAQ

What insider transaction did Crinetics (CRNX) report for its CEO?

Crinetics reported that President & CEO Richard Scott Struthers sold 21,981 shares of common stock on March 16, 2026. The sales were open-market transactions executed by a broker to satisfy tax withholding obligations tied to vesting restricted stock units.

At what prices did the Crinetics (CRNX) CEO sell his shares?

The CEO’s sales occurred in two tranches with volume-weighted average prices of $37.11 and $37.77 per share. Footnotes note price ranges of $36.42–$37.38 and $37.42–$38.23, with exact breakdowns available from Crinetics upon request.

Why did the Crinetics (CRNX) CEO sell 21,981 shares of stock?

The shares were sold to cover Richard Scott Struthers’ tax withholding obligations from vesting restricted stock units granted in 2022, 2023, and 2024. The disposition was executed by a broker under a pre-established Rule 10b5-1 trading plan.

How many Crinetics (CRNX) shares does the CEO hold after this Form 4?

After the reported transactions, Richard Scott Struthers directly owns 404,778 shares of Crinetics common stock. The filing also lists additional indirect holdings controlled through several family trusts and his spouse, which are reported separately from his direct ownership.

Was the Crinetics (CRNX) CEO’s stock sale pre-planned under Rule 10b5-1?

Yes. The filing states the disposition was effected by a broker pursuant to instructions in a Rule 10b5-1 trading plan. Such plans are pre-arranged trading programs that allow insiders to sell shares on a scheduled basis, independent of subsequent market conditions.

Are the Crinetics (CRNX) CEO’s sales indicative of discretionary selling?

The filing characterizes the transactions as sales to satisfy tax withholding tied to vesting restricted stock units. It also notes they were executed under a Rule 10b5-1 trading plan, suggesting a structured, pre-planned mechanism rather than an ad hoc discretionary sale decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Struthers Richard Scott

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		13,196	D	$37.11(2)	413,563	D
Common Stock	03/16/2026		S(1)		8,785	D	$37.77(3)	404,778	D
Common Stock								661,205	I	By Family Trust 1
Common Stock								106,000	I	By Family Trust 2
Common Stock								110,000	I	By Family Trust 3
Common Stock								100,000	I	By Family Trust 4
Common Stock								1,000	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)